Becit Merve, Aydin Sevtap
Atatürk University, Faculty of Pharmacy, Department of Pharmacology, Erzurum, Turkey.
Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Ankara, Turkey.
Turk J Pharm Sci. 2020 Feb;17(1):1-6. doi: 10.4274/tjps.galenos.2018.97759. Epub 2020 Feb 19.
In the treatment of cancer, it is intended to increase the anticancer effect and decrease cytotoxicity using various plant-derived phenolic compounds with chemotherapeutic drugs. Pycnogenol (PYC), a phenolic compound, has been the subject of many studies. Since the mechanisms of the interactions of PYC with cisplatin need to be clarified, we aimed to determine the effects of PYC on cisplatin cytotoxicity in human cervix cancer cells (HeLa) and to evaluate the genotoxicity of PYC.
The cytotoxicity of cisplatin and PYC was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in HeLa cells for 24 h and 48 h. The effect of PYC against oxidative DNA damage was evaluated using the comet assay.
The IC values of cisplatin were 22.4 μM and 12.3 μM for 24 h and 48 h, respectively. The IC values of PYC were 261 μM and 213 μM for 24 h and 48 h, respectively. For 24 h exposure, PYC significantly reduced the IC value of cisplatin at the selected concentrations (15.6-500 μM). For 48 h exposure, PYC did not change the cytotoxicity of cisplatin at concentrations between 15.6 and 125 μM, but significantly reduced it at concentrations of 250 μM and 500 μM. PYC alone did not induce DNA damage at concentrations of 10 μM or 25 μM; however, it significantly induced DNA damage at higher concentrations (50-100 μM). It also significantly reduced HO-induced DNA damage at all concentrations studied (10-100 μM).
Our results suggest that PYC may increase the cisplatin cytotoxicity in HeLa cells at nongenotoxic doses. The results might contribute to the anticancer effect of cisplatin with PYC in cervical carcinoma, but in order to confirm this result further studies with cancer cell lines and studies are needed.
在癌症治疗中,旨在通过将各种植物来源的酚类化合物与化疗药物联合使用来增强抗癌效果并降低细胞毒性。碧萝芷(PYC),一种酚类化合物,已成为众多研究的对象。由于PYC与顺铂相互作用的机制需要阐明,我们旨在确定PYC对人宫颈癌细胞(HeLa)中顺铂细胞毒性的影响,并评估PYC的遗传毒性。
通过3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)法在HeLa细胞中检测顺铂和PYC的细胞毒性,作用时间为24小时和48小时。使用彗星试验评估PYC对氧化性DNA损伤的影响。
顺铂在24小时和48小时的IC值分别为22.4μM和12.3μM。PYC在24小时和48小时的IC值分别为261μM和213μM。对于24小时暴露,在选定浓度(15.6 - 500μM)下,PYC显著降低了顺铂的IC值。对于48小时暴露,在15.6至125μM浓度下,PYC未改变顺铂的细胞毒性,但在250μM和500μM浓度下显著降低了其细胞毒性。单独的PYC在10μM或25μM浓度下未诱导DNA损伤;然而,在较高浓度(50 - 100μM)下它显著诱导了DNA损伤。在所有研究浓度(10 - 100μM)下,它也显著降低了过氧化氢诱导的DNA损伤。
我们的结果表明,PYC可能在非遗传毒性剂量下增加HeLa细胞中顺铂的细胞毒性。这些结果可能有助于顺铂与PYC在宫颈癌中的抗癌作用,但为了证实这一结果,还需要进行更多的癌细胞系研究和实验。